Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003782 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,351
- Enrollment target
- 20
- Study locations
NCT00003782: Completed Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
NCT00003782 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 5,351 participants, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003782, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,351 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating women who have undergone surgery for stage I, stage II, or stage IIIA breast cancer with positive axillary lymph nodes.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG doxorubicin
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- California Cancer Center - Fresno
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Scripps Cancer Center at Scripps Clinic - La Jolla
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Pacific Shores Medical Group - Long Beach
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center - Orange
- Comprehensive Cancer Centers of the Desert - Palm Springs
- Stanford Cancer Center at Stanford University Medical Center - Palo Alto
- Sutter Cancer Center - Sacramento
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
- Catholic Healthcare West - Westbay Region - San Francisco
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Kaiser Permanente Medical Center - Vallejo - Vallejo
Alabama
- Comprehensive Cancer Institute - Huntsville
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- CCOP - Western Regional, Arizona - Phoenix
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,351 participants |
| Start Date | 1999-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00003782 record still lists
NCT00003782 is an interventional study that assigns participants to a tested intervention. Its 5,351 participants enrollment target places it among the larger protocols in the corpus, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00003782 names 20 study sites across 5 states, led by California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00003782 about?
NCT00003782 is a clinical study titled "Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective ...
What is the current status of trial NCT00003782?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,351 participants. The study started on 1999-03. Estimated completion is 2012-12.
What conditions does trial NCT00003782 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00003782?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00003782?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003782 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003782's enrollment target sits among peer trials
5,351 27th of 1224 higher than 1,198 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia